Lantern Pharma News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

23.09.24	Lantern Pharma Says FDA Oks Rare Pediatric Disease Designations In MRT, RMS, And Hepatoblastoma (RTTNews)
05.08.24	Lantern Pharma Reports Positive Results From Phase 2 HARMONIC Study In 'never Smokers' With NSCLC (RTTNews)
18.03.24	Recap: Lantern Pharma Q4 Earnings (Benzinga)
15.03.24	Lantern Pharma Earnings Preview (Benzinga)
30.11.23	Lantern Pharma: FDA Grants Orphan Drug Designation For LP-284 In High-Grade B-cell Lymphomas (RTTNews)
03.10.23	Lantern Pharma Publishes Pre-clinical Efficacy Data Of Drug Candidate LP-184 In Glioblastoma (RTTNews)
21.03.23	MÄRKTE USA/Wall Street von Entspannung im Bankensektor gestützt (Dow Jones)
27.10.21	Code Ocean Selected by Lantern Pharma to Power A.I. Focused Computational Research Environment for Oncology Drug Development (PR Newswire)
30.08.21	Lantern Pharma: FDA Grants Additional Orphan Drug Designation For LP-184 - Quick Facts (RTTNews)
19.08.21	Lantern Pharma Reports Positive Data From Preclinical Study With LP-184 In Glioblastoma (RTTNews)
19.08.21	Lantern Pharma Announces Positive Preclinical Data in Glioblastoma (GBM) with Drug Candidate LP-184 and Expands GBM Research Collaboration (PR Newswire)
16.08.21	Lantern Pharma Announces Abstract on Effectiveness of LP-184 in Pancreatic Cancers Accepted for Presentation at the AACR Virtual Special Conference: Pancreatic Cancer (PR Newswire)
11.08.21	Lantern Pharma's LP-184 Gets Orphan Drug Designation In Treatment Of Pancreatic Cancer (RTTNews)
11.08.21	FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-184 in the Treatment of Pancreatic Cancer (PR Newswire)
29.07.21	Lantern Pharma Reports Second Quarter 2021 Financial Results and Operational Highlights (PR Newswire)
27.07.21	Lantern Pharma Reacquires Rights To Phase 2 Clinical Trial In Metastatic Prostate Cancer (RTTNews)
27.07.21	Lantern Pharma Reacquires Rights to Phase 2 Clinical Trial in Metastatic Prostate Cancer and Global Development & Commercialization of Irofulven (LP-100) from Allarity Therapeutics A/S (PR Newswire)
20.07.21	Lantern Pharma Announces Significant Positive Preclinical Data in Pancreatic Cancer With Drug Candidate LP-184 (PR Newswire)
08.12.20	IPO Lockup Expiration Alert: Lantern Pharma (LTRN) (RTTNews)
20.08.20	JNJ Acquires MNTA, FDA Strikes Down BMRN's Gene Therapy, BLRX's GENESIS On Track, TPTX On Watch (RTTNews)
04.06.20	What's On The Healthcare IPO Calendar Friday? (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

CieFinRichemont	125.85	2.57 %	K V
Sika	232.30	1.84 %	K V
Swiss Re	132.20	1.58 %	K V
Logitech Intl	72.56	1.48 %	K V
ABB	51.02	1.47 %	K V
Nestle	76.60	0.16 %	K V
Sonova Hldg	300.80	0.00 %	K V
Novartis	93.14	-0.14 %	K V
Swisscom	507.00	-0.29 %	K V
Alcon	78.06	-0.41 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Lantern Pharma Inc Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten